

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BUEB ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/001166

FILED: 4 FEBRUARY 2005

U.S. APPLICATION NO:

35 USC §371 DATE:

FOR: MICROEMULSION FORMULATIONS COMPRISING PARTICULAR
SUBSTANCE P ANTAGONISTS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/001166, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614



Gregory C. Houghton
Attorney for Applicant
Reg. No. 47,666

Date: 7/20/06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33613-US-PCT
APPLICATION NO.
Not yet known
APPLICANT
Bueb et al.
FILING DATE
Herewith

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,319,917	11/20/06	Gerspacher et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Gerspacher et al., "Dual neurokinin NK1/NK2 antagonists: N'-(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoylallyl-N-methyl-3,5-bis(trifluoromethyl)benzamides and 3-N'-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N'-methylhydrazinol-N'-(R)-2-oxo-acepan-3-ylpropionamides," Bioorganic & Medicinal Chemistry Letters, Vol. 11(23), pp. 3081-3084 (2001)
	AS	Zabka M., "Colloidal drug delivery systems - Current state and perspectives III. Microemulsions as drug delivery vehicles," Farmaceuticky Obzor 2003 Slovakia, Vol. 72(No. 4-5), pp. 87-92 (2003)
	AT	Hauss D. J., "Lipid-based systems for oral drug delivery: Enhancing the bioavailability of poorly water soluble drugs," American Pharmaceutical Review 2002 United States, Vol. 5(4), pp. 22-28 (2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.